<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616923</url>
  </required_header>
  <id_info>
    <org_study_id>137506</org_study_id>
    <nct_id>NCT05616923</nct_id>
  </id_info>
  <brief_title>Topical MAPK Inhibition in Rosacea</brief_title>
  <acronym>TOMIR</acronym>
  <official_title>Topical MAPK Inhibition in Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albany Research Institute, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, vehicle controlled, double blinded study to evaluate the safety and&#xD;
      potential efficacy of a topical formulation of a MEK inhibitor in patients with&#xD;
      erythematotelangiectatic rosacea&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study will be 22 days. Subjects will use a cream with a MEK inhibitor on&#xD;
      one cheek, and a cream lacking the inhibitor (vehicle control) on the other. Patients will&#xD;
      receive a randomized set of creams for the right and left cheek, one containing the active&#xD;
      ingredient. Subjects will be evaluated on days 1, 8, 15 and 22. Skin appearance will be&#xD;
      scored in each visit. A blood sample will be obtained to determine the levels of systemic&#xD;
      drug absorption.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Each patient will receive two creams labeled &quot;right cheek&quot; or &quot;left cheek&quot;, one containing the active ingredient and the other serving as vehicle control. The labels of each bottle were randomized and the contents of each remains blinded to both the subject and the investigator.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Allocation of drug to cheek side for each bottle set is known only to an investigator not involved in patient assessment and will be unmasked only at the end of the trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in dermatologic score</measure>
    <time_frame>22 days</time_frame>
    <description>Weekly assessment of skin irritation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic drug absorption</measure>
    <time_frame>22 days</time_frame>
    <description>Blood levels of trametinib will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rosacea, Erythematotelangiectatic</condition>
  <arm_group>
    <arm_group_label>Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cheek describing the active compound (topical cream containing 0.1 mg/g trametinib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cheek receiving cream without active compound (topical cream lacking active ingredient)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Topical cream containing 0.1 mg/g trametinib</description>
    <arm_group_label>Trametinib</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Erythematotelangiectatic rosacea diagnosed by a clinician in the centrofacial and/or&#xD;
             ocular regions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other concurrent diseases for which treatment is being received that would preclude&#xD;
             the use of trametinib (i.e., pleural effusion, active infection, intracranial&#xD;
             bleeding)&#xD;
&#xD;
          -  History of skin allergic reactions or documented allergic reaction to trametinib&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Heart failure or other heart disease&#xD;
&#xD;
          -  Active use of medications with known documented interactions with trametinib&#xD;
             (Chloroquine, Ritonavir, Loperamide, Penicillamine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leahrut Saavedra, MS</last_name>
    <phone>518-626-6501</phone>
    <email>leahruth.saavedra@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samuel S. Stratton VA Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leahruth Saavedra, MS</last_name>
      <phone>518-626-6501</phone>
      <email>leahruth.saavedra@va.gov</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Busingye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

